The Ruthenium Complex <Emphasis Type="Italic">cis</Emphasis>-(Dichloro)Tetraammineruthenium(III) Chloride Presents Immune Stimulatory Activity on Human Peripheral Blood Mononuclear Cells

Ruthenium compounds in general are well suited for medicinal applications. They have been investigated as immunosuppressants, nitric oxide scavengers, antimicrobial agents, and antimalarials. The aim of this study is to evaluate the immunomodulatory activity of cis-(dichloro)tetraammineruthenium(III) chloride (cis-[RuCl₂(NH₃)₄]Cl) on human peripheral blood mononuclear cells (PBMC). The cytotoxic studies performed here revealed that the ruthenium(III) complex presents a cytotoxic activity towards normal human PBMC, only at very high concentration. Results also showed that cis-[RuCl₂(NH₃)₄]Cl presents a dual role on PBMC stimulating proliferation and interleukin-2 (IL-2) production at low concentration and inducing cytotoxicity, inability to proliferate, and inhibiting IL-2 production at high concentration. The noncytotoxic activity of cis-[RuCl₂(NH₃)₄]Cl at low concentration towards PBMC, which correlates with the small number of annexin V positive cells and also the absence of DNA fragmentation, suggest that this compound does not induce apoptosis on PBMC. For the first time, we show that, at low concentration (10–100 μg L⁻¹), the cis-[RuCl₂(NH₃)₄]Cl compound induces peripheral blood lymphocytes proliferation and also stimulates them to IL-2 production. These results open a new potential applicability of ruthenium(III) complexes as a possible immune regulatory compound acting as immune suppressor at high concentration and as immune stimulator at low concentration.     

Synthesis and structures of platinum(II) complexes with 5-ferrocenylpyrimidine

Reaction of platinum(II) salts with 5-ferrocenylpyrimidine (FcPM) afforded cis-[Pt(NH₃)₂(FcPM)₂](PF₆)₂ (1), trans-[Pt(NH₃)₂(FcPM)₂](PF₆)₂ (2), cis-[PtCl₂(FcPM)₂] (3), and cis-[PtCl₂(DMSO)(FcPM)] (4): their spectroscopic and electrochemical properties were investigated. Complexes 1 and 2 were structurally characterized by X-ray crystallography.     

Cis-dichlorodiammineplatinum(II) has a binding specificity for adjoining guanine bases

Self complementary deoxyribooctanucleotides, [5′-d(GpGpTpCpGpApCpC)-3′]₂ and [5’-d(CpGpGp- ApTpCpCpG)-3’]₂, were allowed to react with cis- PtCl₂(NH₃)₂, and the reaction mixture was treated with exonuclease (snake venom phosphodiesterase and/or calf spleen phosphodiesterase). Semi-quantitative analysis by HPLC showed that the adjoining guanine bases have a specific binding affinity to cis-PtCl₂(NH₃)₂.     

Synthesis of ruthenium(II) monosubstituted squarates: 1. Procedural considerations

Attempted syntheses of ruthenium(II) monosubstituted squarate complexes in acetonitrile using cis-[RuCl₂(dmso)₄] and anisole-, methoxy-, methyl- and diphenylamino-squarate ligands, respectively, resulted in the formation in each case of the monomer cis, fac-Ru(CH₃CN)Cl₂(dmso)₃ (1) with the ruthenium atom in a distorted octahedral environment. A second crop of crystals harvested from the reaction with the methoxysquarate ligand was identified as the oxalato-bridged dimer [{cis-(CH₃CN)(Cl)(dmso)₂Ru}₂(μ-C₂O₄)] (2). When cis-[RuCl₂(dmso)₄] and methylsquarate were reacted in aqueous solution instead of acetonitrile, the dimer [{fac-(Cl)(dmso)₃Ru}₂(μ-C₂O₄)] (3) was produced. The dimers 2 and 3 are formed from oxidation/ring opening of the methoxy- and methyl-squarate ligands, respectively. Use of the salts of these ligands instead of their non-ionised forms under different reaction conditions, afforded [Na] fac-[RuCl₃(dmso)₃] (4) and [(C₄H₉)₄N]₂[(C₄O₄)(C₄H₂O₄)₂] (7), respectively, which were shown to be products of competing reactions. The information acquired from these failed attempts has provided the basis for the development of a strategy to overcome these problems and lead to a successful synthetic route to ruthenium(II) monosubstituted squarates.     

Mutagenic and Genotoxic Effects of <Emphasis Type="Italic">cis</Emphasis>-(Dichloro)tetraammineruthenium(III) Chloride on Human Peripheral Blood Lymphocytes

Chemotherapeutic agents play an important role in cancer treatment mostly due their systemic action on human organism allowing access to liquid tumors and even metastases. Among these drugs, ruthenium compounds have been showing promising results to treat tumors and represent an important development of new antitumor therapy. This study presents the evaluation of cis-(dichloro)tetraammineruthenium(III) chloride, cis-[RuCl₂(NH₃)₄]Cl, genotoxic effects using human peripheral blood lymphocytes cultured in vitro. Mitotic index (MI), chromosome aberrations (CA), and DNA damage using the comet assay were analyzed. MI in human peripheral blood lymphocyte cultures treated with 1, 10, 100, and 1,000 μg mL⁻¹ cis-[RuCl₂(NH₃)₄]Cl were 5.9%, 4.6%, 3.9%, and 0%, respectively. Doxorubicin chloridate was used as the positive control. CA derived from 1, 10, and 100 μg mL⁻¹ concentrations were defined as spontaneous when compared with the negative control, and at the concentration of 1,000 μg mL⁻¹, the cell cycle was inhibited (IM = 0%). Results obtained for the comet assay using cis-[RuCl₂(NH₃)₄]Cl suggest that this compound has no genotoxic activity against cultured human peripheral blood lymphocytes.     

Versatile coordination behaviour of Ph2AsCH2AsPh2 with Ru(II)

Treatment of ‘RuCl₃ · 3H₂O’ with Ph₂AsCH₂AsPh₂ (dpam) in hot EtOH gives either trans-[RuCl₂(dpam-As,As′)(dpam-As)₂] (1), or cis-[RuCl₂(dpam-As,As′)₂] (2), depending on the mole ratio. On exposure to light, solutions of 2 isomerise to trans-[RuCl₂(dpam-As,As′)₂] (3). Treatment of [RuCl₂(PPh₃)₃] with two equivalents of dpam in CH₂Cl₂ gave a mixture of two products, from which trans-[RuCl₂(PPh₃) (dpam-As,As′)(dpam-As)] (4) was isolated by recrystallisation. The crystal structures of 1-4 are reported. Complexes 1-3 in CH₂Cl₂ undergo electrochemical oxidation to Ru(III), and the Ru(III) form of 2 undergoes isomerisation on the voltammetric timescale to the Ru(III) form of 3.     

The Ruthenium Complex cis-(Dichloro)tetraammineruthenium(III) Chloride Presents Selective Cytotoxicity Against Murine B Cell Lymphoma (A-20), Murine Ascitic Sarcoma 180 (S-180), Human Breast Adenocarcinoma (SK-BR-3), and Human T Cell Leukemia (Jurkat) Tumor Cell Lines

The aim of present study was to verify the in vitro antitumor activity of a ruthenium complex, cis-(dichloro)tetraammineruthenium(III) chloride (cis-[RuCl₂(NH₃)₄]Cl) toward different tumor cell lines. The antitumor studies showed that ruthenium(III) complex presents a relevant cytotoxic activity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) cell lines and a very low cytotoxicity toward human peripheral blood mononuclear cells. The ruthenium(III) complex decreased the fraction of tumor cells in G0/G1 and/or G2-M phases, indicating that this compound may act on resting/early entering G0/G1 cells and/or precycling G2-M cells. The cytotoxic activity of a high concentration (2 mg mL^?1) of cis-[RuCl₂(NH₃)₄]Cl toward Jurkat cells correlated with an increased number of annexin V-positive cells and also the presence of DNA fragmentation, suggesting that this compound induces apoptosis in tumor cells. The development of new antineoplastic medications demands adequate knowledge in order to avoid inefficient or toxic treatments. Thus, a mechanistic understanding of how metal complexes achieve their activities is crucial to their clinical success and to the rational design of new compounds with improved potency.     

Competitive ligation between carbon monoxide and propiononitrile in chloro-complexes of platinum(II)

EtCN partially displaces coordinated carbon monoxide from cis-PtCl₂(CO)₂ giving an equilibrium mixture of the two geometrical isomers of PtCl₂(CO)(NCEt), together with unreacted cis-PtCl₂(CO)₂, as monitored by IR and NMR measurements. The equilibrium has also been studied starting from PtCl₂(NCEt)₂, through displacement of coordinated EtCN by CO. The equilibrium constant of the reaction between PtCl₂(CO)(NCEt) [cis + trans] and CO to produce cis-PtCl₂(CO)₂ (48 ± 6, corresponding to ΔG⁰ = −9.5 ± 0.3 kJ mol⁻¹) has been measured at 23.4 °C, in the presence of SnCl₂ as catalyst, the uncatalysed reaction being exceedingly slow. With an appropriate control of the CO partial pressure, PtCl₂(CO)(NCEt) was obtained in a nearly quantitative yield either from cis-PtCl₂(CO)₂ + EtCN or from PtCl₂(NCEt)₂ + CO. The molecular and crystal structure of cis-PtCl₂(CO)(NCEt) has been solved by X-ray diffractometry.     

Platinum(II) triammine antitumour complexes: structure-activity relationship with guanosine 5′-monophosphate (5′-GMP)

The multinuclear (¹H, ¹⁵N, ³¹P and ¹⁹⁵Pt) NMR spectroscopies, ES-MS and HPLC have been employed to investigate the structure-activity relationship for the reactions between guanosine 5′-monophosphate (5′-GMP) and the platinum(II)-triamine complexes of the general formulation cis-[Pt(NH₃)₂(Am)Cl]NO₃ (where Am represents a substituted pyridine). The order of reaction rate of the reactions was found to be: 3-phpy > 4-phpy > py > 4-mepy > 3-mepy > 2-mepy. The two basic factors, steric and electronic, were attributed to the order of the binding rate constants. A possible mechanism of the reaction of cis-[Pt(NH₃)₂(Am)Cl]⁺ with 5′-GMP suggested that the reactions proceed via direct nucleophilic attack and no loss of ammonia. cis-[Pt(NH₃)₂(Am)Cl]⁺ binds to the N7 nitrogen of the guanine residue of 5′-GMP to form a coordinate bond with the Pt metal centre. This mechanism is apparently different from that of cisplatin. The pK_a value of cis-[Pt(NH₃)₂(4-mepy)(H₂O)](NO₃)₂ (5.63) has been determined at 298 K by the use of distortionless enhancement by polarization transfer (DEPT) ¹⁵N NMR spectroscopy and compared to the pK_a value of cis-[PtCl(H₂O)(NH₃)₂]⁺.     

Ruthenium-modified proteins. Reactions of cis-[ Ru(NH3)4(OH2)2]2+ and cis-[ Ru(en)2(OH2)2]2+ with azurin,myoglobin and cytochrome c

Reactions of cis-[Ru(en)₂(OH₂)₂]²⁺ (or cis-[Ru (NH₃)₄(OH₂)₂]²⁺) with Pseudomonas aeruginosa azurin (Az), horse heart myoglobin (Mb^h), and horse heart cytochrome c (cyt c) give Ru-labelled proteins. The ruthenium binding sites in the singly modified derivatives are His-83 (Az), His-81 (Mb^h), and His-33 (cyt c). Spectroscopic and electrochemical measurements indicate that the structures of the proteins are not perturbed by the surface-bound ruthenium complexes. The E°_f values of the Ru(III)/(II) couple in these Ru-modified proteins fall between −0.07 and −0.13 V vs. NHE.     

Copper-thioarylazoimidazole complexes: Structures, photochromism and redox interconversion between Cu(II) ↔ Cu(I) and correlation with DFT calculation

Reaction of Cu(ClO₄)₂·6H₂O, SRaaiNR′ (1-alkyl-2-[(o-thioalkyl)phenylazo]imidazole) and NH₄SCN (1:1:2 mol ratio) affords distorted square pyramidal, [Cu^II(SRaaiNR′)(SCN)₂] (3) compound while identical reaction with [Cu(MeCN)₄](ClO₄) yields -SCN- bridged coordination polymer, [Cu^I(SRaaiNR′)(SCN)]_n (4). These two redox states [Cu^II and Cu^I] are interconvertible; reduction of [Cu^II(SRaaiNR′)(SCN)₂] by ascorbic acid yields [Cu^I(SRaaiNR′)(SCN)]_n while the oxidation of [Cu^I(SRaaiNR′)(SCN)]_n by H₂O₂ in presence of excess NH₄SCN affords [Cu^II(SRaaiNR′)(SCN)₂]. They are structurally confirmed by single crystal X-ray diffraction study. Cyclic voltammogram of the complexes show Cu(II)/Cu(I) redox couple at ∼0.4 V and azo reductions at negative to SCE. UV light irradiation in MeCN solution of [Cu^I(SRaaiNR′)(SCN)]_n (4) show trans-to-cis isomerisation of coordinated azoimidazole. The reverse transformation, cis-to-trans, is very slow with visible light irradiation while the process is thermally accessible. Quantum yields (?_t→c) of trans-to-cis isomerisation are calculated and free ligands show higher ? than their Cu(I) complexes. The activation energy (E_a) of cis-to-trans isomerisation is calculated by controlled temperature experiment. Copper(II) complexes, 3, do not show photochromism. DFT and TDDFT calculation of representative complexes have been used to determine the composition and energy of molecular levels and results have been used to explain the solution spectra, photochromism and redox properties of the complexes.     

Synthesis of amidate-hanging platinum mononuclear complexes by base hydrolysis of nitrile complexes

The “amidate-hanging” Pt mononuclear complexes, which can easily bind a second metal ion with the non-coordinated oxygen atoms in the amidate moieties, have been synthesized and characterized by ¹H NMR, MS, IR spectroscopy, and single crystal X-ray analysis. Five new complexes with various amidate ligands and co-ligands, cis-[Pt(PVM)₂(en)] · 4H₂O (1, PVM = pivaloamidate, en = ethylenediamine), cis-[Pt(PVM)₂(NH₂CH₃)₂] · H₂O (2), cis-[Pt(PVM)₂(NH₂^tBu)₂] (3), cis-[Pt(TCM)₂(NH₃)₂] (4, TCM = trichloroacetamidate), and cis-[Pt(BZM)₂(NH₃)₂] (5, BZM = benzamidate), were successfully synthesized by direct base hydrolysis of the corresponding Pt nitrile complexes, cis-[Pt(NCR)₂(Am)₂]²⁺ (P1, P2, P3, and P5) (NCR = nitrile, Am = amine). These nitrile complexes were obtained by introducing nitriles into the Pt aqua complexes, cis-[Pt(OH₂)₂(Am)₂](ClO₄)₂, whereas introduction of trichloronitrile into [Pt(OH₂)₂(NH₃)₂](ClO₄)₂ induced more facilitated water nucleophilic attack to afford [Pt(TCM)(NH(COH)CCl₃)(NH₃)₂](ClO₄) (P4). The base treatments of the precursor complexes (P1-5) lead to produce “amidate-hanging” Pt mononuclear complexes (1-5) without geometry isomerization. The ¹⁹⁵Pt chemical shifts for 1-5 exhibit subtle differences of the Pt electron densities among them.     

In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A

A series of novel octahedral ruthenium(III) complexes involving 6-benzylaminopurine (L) derivatives as N-donor ligands has been prepared by the reaction of [(DMSO)₂H][trans-RuCl₄(DMSO)₂] with the corresponding L derivative. The complexes 1-12 have the general compositions trans-[RuCl₄(DMSO)(n-Cl-LH)] ⋅ xSol (1-3), trans-[RuCl₄(DMSO)(n-Br-LH)] · xSol (4-6), trans-[RuCl₄(DMSO)(n-OMe-LH)] · xSol (7-9) and trans-[RuCl₄(DMSO)(n-OH-LH)] · xSol (10-12); n = 2, 3, and 4, x = 0-1.5; and Sol = H₂O, DMSO, EtOH and/or (Me)₂CO. The complexes have been thoroughly characterized by elemental analysis, UV-visible, FTIR, Raman, and EPR spectroscopy, ES + (positive ionization electrospray) mass spectrometry, thermal analysis, cyclic voltammetry, magnetic and conductivity measurements. The X-ray molecular structure of trans-[RuCl₄(DMSO)(3-Br-LH)] ⋅ (Me)₂CO (5) revealed the distorted octahedral coordination in the vicinity of the central atom, and also confirmed that the 3-Br-L ligand is present as the N3-protonated N7-H tautomer and is coordinated to Ru(III) through the N9 atom of the purine moiety. The tested complexes have been found to be in vitro non-cytotoxic against K562, G361, HOS and MCF7 human cancer cell lines with IC₅₀ > 100 μM in contrast to the moderate results regarding the antiradical activity with IC₅₀ ≈ 10^− 3 M. On the contrary, in vivo antitumor activity screening showed that the prepared Ru(III) complexes possess higher pro-apoptotic activity than NAMI-A. The reduction of Ru(III) to Ru(II) and Ru(II)-species formation in tumor tissues was confirmed by means of a simple method of detection and visualization of intracellular Ru(II) by fluorescence microscopy. The originality of this method is based on the preparation of a Ru(II)-bipyridine complex in situ.     

Catalytic effect of cis-diammineplatinum α-pyrrolidone tan adsorbed on a platinum electrode in electrochemical oxidation of water into molecular oxygen

Cyclic voltammograms of cis-diammineplatinum α-pyrrolidone-blue and -tan, [Pt₄(NH₃)₈(C₄H₆NO)₄]ⁿ⁺ (n = 5 and 6, respectively) show for either complex only one redox peak at 0.53 V (average potential of the anodic and cathodic peak potentials). Coulometry and UVVis spectra of bulk- electrolyzed solution indicated that the redox peak corresponds to the reaction [Pt₄(NH₃)₈(C₄H₆NO)₄]⁸⁺ + 4e ⇄ 2[Pt₂(NH₃)₄(C₄H₆NO)₂]²⁺. When cyclic voltammetry is carried out in a solution of [Pt₄(NH₃)₈(C₄H₆NO)₄]⁶⁺ or a platinum electrode adsorbed with [Pt₄(NH₃)₈(C₄H₆NO)₄]⁶⁺ is used in the presence of oxidizing agent in the solution, O₂ gas generates from the electrode surface with large catalytic cathodic current at potentials below ca. 0.8 V. The O₂ gas was confirmed to generate from water by GC-MS analysis. This abnormal O₂ generation phenomenon is explained with cyclic reactions of chemical surface oxide formation on the electrode by the oxidizing agent and electrochemical reduction of the surface oxide. Oxygen gas generates from the reaction of [Pt₄(NH₃)₈(C₄H₆NO)₄]⁸⁺ or [Pt₄(NH₃)₈(C₄H₆NO)₄]⁶⁺ with OH⁻ produced in the course of the electrochemical reduction of the electrode surface oxide. The ability of [Pt₄(NH₃)₈(C₄H₆NO)₄]⁸⁺ and [Pt₄(NH₃)₈(C₄H₆NO)₄]⁶⁺ to oxidize OH⁻ into O₂ has been reported previously.     

Unexpected formation and structure elucidation of mer-[RuCl3(TMSO)(bpy)] derived from [H(TMSO)][trans-RuCl4(TMSO)2] under mild condition

Treatment of [H(TMSO)][trans-RuCl₄(TMSO)₂] (1) with 2,2′-bipyridine (bpy) in ethanol at room temperature resulted an unknown mer-[RuCl₃(TMSO)(bpy)] (3) and a known cis-[RuCl₂(TMSO)₄] (4) (TMSO =  tetramethylene sulfoxide) complexes. The 3 was obtained by the substitution with bpy in mer-[RuCl₃(TMSO)₃] (2), whereas 4 was obtained by one-electron reduction of 2, suggesting that 2 is a precursor for both 3 and 4. The structure of 3 was determined by single crystal X-ray diffraction. The reaction is a new synthetic procedure for 3 and/or 3 and 4 in mild reaction conditions from the anionic complex 1. It involves simultaneous substitution and redox reaction. This is the first known example of precisely characterized Ru(III)-chloride-TMSO-bpy-complex derived from anionic [H(TMSO)][trans-RuCl₄(TMSO)₂] at room temperature.     

The first report on specific binding mode of diethylmalonate acting as a bridging ligand between ruthenium (II) ions stabilized by intramolecular hydrogen bonds

Typically 2,2-diethylmalonate (dem) acts as a chelating ligand and binds to the metal in a η² (dem-O, O′) mode. However, when cis,fac-[RuCl₂(TMSO-S)₄] is treated with K₂(dem), it prefers to bind in an unusual bridging mode (μ-dem-O, O′) with the ruthenium (II) cation containing coordinated water, forming a strong hydrogen bond with the non-coordinated oxygen atoms of the 2,2-diethylmalonate ligand. The reaction products of cis,fac-[RuCl₂(TMSO-S)₄] (1) and cis,fac-[RuCl₂(DMSO-S)₃(DMSO-O)] (2) with dem are the dinuclear species with two bridging dem units, fac-[Ru(TMSO-S)₃(H₂O)(μ²-dem-O, O′)]₂ (3) and fac-[Ru(DMSO-S)₃(H₂O)(μ²-dem-O, O′)]₂ (4), respectively. The complex 3 was characterized by X-ray crystallography in which water ligands occupy anti positions with respect to each other. The NMR and X-ray study support each other with respect to dinuclear structure of 3 and 4, indicating that the dinuclear structure observed in the solid state is preserved in solution as well. The mononuclear anionic complex with chelating dem unit, K{fac-[RuCl(η²-dem-O, O′)(TMSO-S)₃} (5), was also isolated from the reaction of 1 and K₂(dem) demonstrating that 5 is an intermediate in the formation of 3.     

Homogeneous CO hydrogenation and transfer hydrogenation catalyzed by ruthenium(II) complexes containing optically active Ph2PCH(Ph)CH(Me)NH2 and 1,2-C5H8(PPh2)2 ligands

Combination of (1S,2S)-cyclopentanediylbis(diphenylphosphine) with [Ru(η⁴-C₈H₁₂){η³-(CH₂)₂CMe}₂] afforded the chelate complex [Ru{η³-(CH₂)₂CMe}₂{(1S,2S)-C₅H₈(PPh₂)₂}] (1), which gave (OC-6-13)-[RuCl₂{(1S,2S)-C₅H₈(PPh₂)₂}{(1S,2S)-Ph₂PCH(Ph)CH(Me)NH₂}] (2) upon reaction with methanolic HCl in acetone, followed by the addition of the β-aminophosphine in DMF. The (P ∩ N)₂-chelated complexes (OC-6-13)-[RuCl₂{(1S,2S)-Ph₂PCH(Ph)CH(Me)NH₂}₂] (3) and (OC-6-13)-[RuCl₂{(1R,2S)-Ph₂PCH(Ph)CH(Me)NH₂}₂] (4) resulted from RuCl₃ · 3H₂O and the P,N ligands under reducing conditions. The crystal structures of 3 and 4 were determined by single-crystal X-ray diffraction. Following activation by KOBu-t in isopropanol, compounds 2–4 catalyzed the enantioselective transfer hydrogenation of acetophenone with i-PrOH as the hydrogen source as well as the direct hydrogenation of the ketone by H₂ in low to moderate e.e. (up to 67%).     

Dinuclear complexes with a μ-cyano ligand. Part X. Synthesis and characterization of several derivatives of cis-diaquaamminecobalt(III) complexes. Influence of pH

Six new dinuclear complexes, derived from cis-[Co(H₂O)₂(NH₃)₄]³⁺, cis-[Co(H₂O)₂(en)₂]³⁺ and [M(CN)₄^2? (M = Ni, Pd, Pt) were prepared and characterized by means of chemical analysis, electronic and IR measurements. The influence of the pH on the rate of the reaction was studied for the two derivatives of [Pd(CN)₄]^2?, showing that the best conditions to obtain the dinuclear compounds are at pH near 6, where the predominant species are cis-[Co(OH)(H₂O)(amine)₂]²⁺. The [Pt(CN)₄]^2? derivatives show PtPt interactions both in the solid state and in solution.     

Oligophosphine ligands. XIII. Halo and hydro complexes of ruthenium(II) containing the novel tripod tetrakis(tertiary) phosphine P(CH2CH2CH2PMe2)3

The reaction of the ruthenium complexes RuCl₂(PPh₃)₃, RuCl₂(PPh₃)₄, RuCl₂(PMe₃)₄, RuCl₂(Me₂SO)₄, or RuBr₂(PPh₃)₃ with the tripod tetrakis(tertiary) phosphine P(CH₂CH₂CH₂PMe₂)₃ gave the compounds cis-RuCl₂ [P(CH₂CH₂CH₂PMe₂)₃] (1) and cis-RuBr₂[P(CH₂CH₂CH₂PMe₂)₃] (2). The coordination geometry of 1 and 2 was derived from the ABX₂ type ³¹P NMR patterns of the complexes, as well as from an X-ray structure determination for the chloride 1. Crystals of 1 were found to be monoclinic, space group P2₁/n (Z = 4), with a = 942.0(3), b = 1446.2(4), c = 1680(1) pm, and β = 104.99(4)°. Anisotropic refinement of the structure converged at R = 0.040 and R_w = 0.034 (3318 data). Selected bond lengths are (in pm): RuP(CH₂−)Me₂ (trans-atom P), 235.8(1) and 239.3(1); RuP(CH₂−)Me₂ (trans-atom Cl), 227.9(1); RuP(CH₂−)₃, 225.3(1); RuCl (trans-group P(CH₂−)₃), 252.1(1); and RuCl (trans-group P(CH₂)Me₂), 250.5(1). Reaction of 1 with LiAlH₄ yielded the hydro derivatives cis-Ru(H)Cl[P(CH₂CH₂CH₂PMe₂)₃] (3) and cis-RuH₂[P(CH₂CH₂CH₂PMe₂)₃] (4), which were characterized by IR and ¹H and ³¹p NMR spectroscopy.     

Effect of thiol-functionalised silica on cisplatin adsorption

This study contributes to the investigation related to guest–host interactions between the chemotherapeutic agent cisplatin and a functionalised silica matrix in order to improve and find new materials such as drug carriers. The adsorption of cisplatin and its complexes, cis-[PtCl(NH₃)₂]⁺ and cis-[Pt(NH₃)₂]²⁺, on a SH-functionalised SiO₂(111) surface has been studied by the atom superposition and electron delocalisation method. The adiabatic energy curves for the adsorption of the drug and its products on the delivery system were considered. The electronic structure and bonding analysis were also performed. The molecule and their complex are adsorbed on the functionalised surface resulting in a major absorption of the cis-[Pt(NH₃)₂]²⁺ complex. The molecule–surface interactions are formed via –SH group. The molecule/complexes SH electron-donating effect plays an important role in the catalytic reaction. The more important drug–carrier interactions occur through the Cl–H bond for the adsorption of cis-[PtCl₂(NH₃)₂] and cis-[PtCl(NH₃)₂]⁺, and through the Pt–S and Pt–H interactions for cis-[Pt(NH₃)₂]²⁺ adsorption. When the new interactions are formed, the functionalised carrier maintains their matrix properties while the molecule is the most affected after adsorption. The Pt atomic orbitals present the most important changes during adsorption.